Track market-moving stories before they get noisy

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of QIAGEN N.V. (NYSE: QGEN) to the EQT XI fund for €46.50 in cash per share.Halper Sadeh encourages QIAGEN shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation concerns whether QIAGEN and its board of directors violated the federal secu.

22.10.2026 13:23, QIA

Index DAX klesá o 0,94 % na 25 403,75 b.

Německé akcie, měřené indexem DAX, oslabují.

Daří se akciím společnosti QIAGEN (+5,4 %) poté, co se EQT AB dohodla na převzetí firmy za zhruba 9,6 mld. EUR (10,8 mld. USD). Dohoda tak završuje roky spekulací o převzetí evropské firmy zaměřené na molekulární testování. Představenstvo QIAGENu schválilo hotovostní nabídku ve výši 46,50 EUR za akcii od konsorcia vedeného EQT. Součástí konsorcia jsou také Abu Dhabi Investment Authority a kanadský penzijní fond Canada Pension Plan Investment Board.

„Myslíme si, že QIAGEN je převzat za férovou cenu. Vidíme také mnoho výhod v tom, že se společnost dostane do soukromého vlastnictví, vzhledem k nastupujícím dlouhodobým strukturálním trendům a potřebě firmy investovat s dlouhodobým horizontem,“ uvedli analytici Berenbergu.

Po výsledkovém reportu oslabují akcie softwarové společnosti SAP (-1,1 %). Podrobnosti naleznete v samostatné zprávě zde.

Index DAX -0,94 % na 25 403,75 b. Nejsilnější akcie Změna Nejslabší akcie Změna Qiagen (QIA) +5,4 % Siemens Energy (ENR) -3,2 % Merck (MRK) +1,7 % Infineon Technologies (IFX) -2,4 % Rheinmetall AG (RHM) +1,0 % Siemens (SIE) -2,2 % Deutsche Telekom (DTE) +0,9 % Bayer (BAYN) -2,2 % Zalando (ZAL) +0,9 % Deutsche Bank (DBK) -2,1 % Zdroj: Bloomberg

Michal Bárta
Fio banka, a.s.
Prohlášení

Související odkazy Frankfurtská burza ve čtvrtek posílila QIAGEN údajně láká fondy soukromého kapitálu v čele s TPG a Bain Capital Frankfurtská burza uzavřela první obchodní den tohoto týdne v červených číslech Frankfurtská burza v úvodu obchodování posiluje Německé akcie ve čtvrtek posílily

Shares of Qiagen N.V. (NYSE:QGEN – Get Free Report) have been assigned an average rating of “Hold” from the fourteen research firms that are presently covering the stock, Marketbeat.com reports. Nine investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $43.93.

A number of research firms have recently issued reports on QGEN. UBS Group started coverage on Qiagen in a research report on Wednesday, September 9th. They set a “neutral” rating and a $47.00 price target on the stock. Barclays set a $40.00 price objective on Qiagen and gave the company an “equal weight” rating in a report on Friday, August 7th. TD Cowen restated a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. Citigroup reaffirmed a “neutral” rating and issued a $45.00 price objective (up from $38.00) on shares of Qiagen in a research note on Monday, August 10th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Qiagen from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th.

Get Our Latest Research Report on Qiagen

Qiagen Stock Up 5.0% Shares of NYSE:QGEN opened at $48.87 on Wednesday. Qiagen has a 52-week low of $32.53 and a 52-week high of $57.81. The stock has a market cap of $10.07 billion, a P/E ratio of 25.04, a price-to-earnings-growth ratio of 4.63 and a beta of 0.61. The business’s 50 day moving average is $44.01 and its 200 day moving average is $40.45. The company has a quick ratio of 2.31, a current ratio of 2.85 and a debt-to-equity ratio of 0.48. Qiagen (NYSE:QGEN – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.60 by $0.02. The company had revenue of $535.04 million for the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. Qiagen’s quarterly revenue was up .2% on a year-over-year basis. During the same period last year, the business posted $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. Sell-side analysts predict that Qiagen will post 2.43 EPS for the current year.

Institutional Inflows and Outflows Institutional investors have recently added to or reduced their stakes in the business. Engineers Gate Manager LP boosted its position in Qiagen by 107.7% during the 2nd quarter. Engineers Gate Manager LP now owns 74,567 shares of the company’s stock valued at $2,916,000 after acquiring an additional 38,658 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of Qiagen in the 1st quarter valued at $2,518,000. Baader Bank Aktiengesellschaft purchased a new position in shares of Qiagen in the 1st quarter valued at $1,368,000. Public Employees Retirement System of Ohio purchased a new position in shares of Qiagen in the 2nd quarter valued at $2,836,000. Finally, WINTON GROUP Ltd bought a new position in shares of Qiagen in the 2nd quarter worth $1,423,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

About Qiagen (Get Free Report)

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.

Further Reading Five stocks we like better than Qiagen Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling? Halliburton Gains Traction: Multiyear Upcycle Ahead Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) will bring together tuberculosis experts from around the world for the Global TB Clinical and Educational Summit from October 13-16 as a persistent disease burden and growing pressures on global health funding put renewed focus on tuberculosis prevention, screening and care. An estimated 10.7 million people worldwide developed tuberculosis in 2024 and nearly 1.2 million died from the d.

2.10.2026 18:07

Index DAX posílil o 1,17 % na 25230,26 b.

Německý index DAX dnes zakončil v zelených číslech. Největší zisky připsaly akcie Infineon Technologies (+8,8 %), Qiagen (+5,0 %) a Hochtief (+2,8 %). Naopak nejvíce klesaly akcie společnosti Daimler Truck Holding (-2,0 %), SAP (-1,5 %) a Bayer (-1,0 %).

Celoevropský STOXX Europe 600 dnes posiluje o 0,69 %. Nejvíce dnes rostou sektory IT (+2,91 %), základních materiálů (+1,65 %) a průmyslu (+1,46 %). Nedaří se pak sektoru zdravotní péče (-0,92 %) a energií (-0,11 %).

Index DAX +1,17 % na 25230,26 b. Nejsilnější akcie Změna Nejslabší akcie Změna Infineon Technologies (IFX) +8,8 % Daimler Truck Holding AG (DTG) -2,0 % Qiagen (QIA) +5,0 % SAP (SAP) -1,5 % HOCHTIEF AG (HOT) +2,8 % Bayer (BAYN) -1,0 % Siemens Energy (ENR) +2,0 % BMW (BMW) -0,9 % Airbus (AIR) +2,0 % Mercedes-Benz Group AG (MBG) -0,8 % Zdroj: Bloomberg

Jan Prokeš
Fio banka, a.s.
Prohlášení

Envestnet Asset Management Inc. cut its holdings in Qiagen N.V. (NYSE:QGEN – Free Report) by 4.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 359,532 shares of the company’s stock after selling 18,260 shares during the period. Envestnet Asset Management Inc. owned approximately 0.17% of Qiagen worth $14,045,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Manchester Capital Management LLC bought a new stake in shares of Qiagen in the fourth quarter valued at approximately $42,000. Hilltop National Bank bought a new position in Qiagen during the 2nd quarter worth $50,000. Integrated Wealth Concepts LLC bought a new position in Qiagen during the 2nd quarter worth $59,000. Allworth Financial LP raised its holdings in Qiagen by 20.8% in the 2nd quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock valued at $72,000 after acquiring an additional 317 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in Qiagen by 46.8% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,746 shares of the company’s stock valued at $110,000 after acquiring an additional 876 shares in the last quarter. 70.00% of the stock is owned by institutional investors.

Qiagen Stock Down 1.3% QGEN stock opened at $43.82 on Thursday. The firm has a 50-day moving average price of $43.02 and a 200-day moving average price of $39.92. Qiagen N.V. has a 12 month low of $32.53 and a 12 month high of $57.81. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $9.03 billion, a P/E ratio of 22.45, a price-to-earnings-growth ratio of 4.42 and a beta of 0.63.

Qiagen (NYSE:QGEN – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The company had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. During the same period in the previous year, the firm posted $0.60 EPS. The firm’s revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, equities research analysts anticipate that Qiagen N.V. will post 2.43 EPS for the current fiscal year. Analysts Set New Price Targets A number of analysts have recently weighed in on QGEN shares. JPMorgan Chase & Co. upped their target price on Qiagen from $45.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Stifel Nicolaus set a $40.00 price target on Qiagen in a research report on Friday, August 7th. Barclays set a $40.00 price target on Qiagen and gave the company an “equal weight” rating in a research note on Friday, August 7th. TD Cowen reaffirmed a “hold” rating on shares of Qiagen in a research report on Wednesday, July 15th. Finally, Berenberg Bank set a $45.50 price objective on shares of Qiagen and gave the stock a “hold” rating in a research note on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $43.51.

Get Our Latest Report on QGEN

Qiagen Profile (Free Report)

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample technologies, molecular testing solutions and bioinformatics products. The company develops tools that help researchers and healthcare professionals isolate, analyze and interpret biological materials, including DNA, RNA and proteins.

Its portfolio includes laboratory kits and instruments for sample preparation, polymerase chain reaction (PCR), next-generation sequencing, genotyping and molecular diagnostics. QIAGEN also provides digital and bioinformatics solutions used to manage and analyze biological data.

Recommended Stories Five stocks we like better than Qiagen Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors? O’Reilly Automotive’s Stock Slump Hides a Stronger Business McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Qiagen N.V. (NYSE:QGEN – Get Free Report) has been given an average rating of “Hold” by the fourteen brokerages that are covering the company, Marketbeat reports. Nine analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $43.51.

QGEN has been the topic of a number of research analyst reports. Citigroup restated a “neutral” rating and issued a $45.00 target price (up from $38.00) on shares of Qiagen in a research note on Monday, August 10th. Weiss Ratings upgraded Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 11th. JPMorgan Chase & Co. boosted their price objective on Qiagen from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. TD Cowen reissued a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. Finally, UBS Group assumed coverage on shares of Qiagen in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $47.00 price objective on the stock.

View Our Latest Stock Analysis on Qiagen

Hedge Funds Weigh In On Qiagen A number of institutional investors have recently made changes to their positions in QGEN. Norges Bank bought a new position in shares of Qiagen during the fourth quarter valued at about $166,500,000. Deutsche Bank AG increased its holdings in shares of Qiagen by 9.7% in the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock worth $355,614,000 after buying an additional 697,342 shares during the period. Amundi lifted its stake in shares of Qiagen by 12.4% in the 1st quarter. Amundi now owns 4,757,681 shares of the company’s stock valued at $190,498,000 after acquiring an additional 524,959 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of Qiagen in the 1st quarter valued at about $14,647,000. Finally, Troluce Capital Advisors LLC purchased a new stake in Qiagen during the 1st quarter valued at about $14,514,000. Institutional investors own 70.00% of the company’s stock. Qiagen Stock Down 0.9% Shares of NYSE:QGEN opened at $44.15 on Friday. The firm has a fifty day moving average price of $42.79 and a two-hundred day moving average price of $39.89. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31. Qiagen has a one year low of $32.53 and a one year high of $57.81. The company has a market cap of $9.10 billion, a price-to-earnings ratio of 22.62, a PEG ratio of 4.44 and a beta of 0.63.

Qiagen (NYSE:QGEN – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The firm had revenue of $535.04 million for the quarter, compared to analysts’ expectations of $527.50 million. During the same quarter in the prior year, the firm posted $0.60 earnings per share. The business’s quarterly revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. Analysts anticipate that Qiagen will post 2.43 EPS for the current fiscal year.

About Qiagen (Get Free Report)

QIAGEN N.V. is a global provider of sample preparation, molecular testing and bioinformatics solutions used in life sciences research, molecular diagnostics and applied testing. The company develops technologies that help customers isolate and analyze DNA, RNA and other biological materials from blood, tissue and other samples.

Its offerings include laboratory instruments, consumables, assay kits and software. Key product areas include automated sample-processing systems, polymerase chain reaction (PCR) and digital PCR solutions, next-generation sequencing workflows, bioinformatics tools, and diagnostic tests such as QuantiFERON for tuberculosis testing and QIAstat-Dx for syndromic testing.

Recommended Stories Five stocks we like better than Qiagen Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out Oil May Be Stronger Than It Looks—And Diamondback Is on Sale

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways QIAGEN is expanding test menus and automation, with new systems supporting second-half 2026 sales growth. Partnerships are broadening QIAGEN's assay, automation and digital capabilities across key markets. QGEN faces cautious customer spending and competition that may delay platform adoption. QIAGEN N.V. (QGEN - Free Report) is well positioned for growth in the upcoming quarters, supported by continued test menu expansion. Meanwhile, strategic partnerships support assay development and create opportunities for recurring consumables revenues across clinical, research and biopharma markets. However, cautious customer spending, weaker research funding and intense competition may limit near-term growth and delay the adoption of new platforms.

In the past year, shares of this Zacks Rank #3 (Hold) company have lost 7.8% against the industry’s 21.3% growth. The S&P 500 composite has seen a 17.9% rise in the same time frame.

The leading provider of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA has a market capitalization of $9 billion. QIAGEN has earnings yield of 5.56% against the industry’s negative 15.63% yield. 

Let’s delve deeper.

Tailwinds for QGEN Stock Progress With Test Menu Expansion: QIAGEN continues to invest in menu breadth and workflow automation across core platforms. QIAstat-Dx expanded into bloodstream infection testing in Europe with two BCID panels covering 33 pathogens and 28 antimicrobial-resistance markers in about one hour. The Gastrointestinal panel also supported testing during the U.S. Cyclospora outbreak. 

In sample preparation, QIAsymphony Connect was launched, while QIAsprint Connect began customer placements in second-quarter 2026. QIAmini remains on track for launch in fall 2026. Management expects new Sample Technologies systems and other product launches to contribute approximately two percentage points to the sequential improvement in second-half 2026 sales.

Strategic Collaborations to Drive Growth: QIAGEN uses strategic partnerships to expand assay development, automation and digital capabilities across its portfolio. In companion diagnostics, pharmaceutical collaborations support multi-year co-development programs and recurring consumables opportunities as associated therapies advance. The company is also working with DiaSorin and Inpeco on a fully automated QuantiFERON workflow targeted for the second half of 2027. In digital PCR, its collaboration with Hamilton is extending QIAcuity automation for cell and gene therapy applications. 

QDI is also partnering with NVIDIA to combine curated biomedical knowledge with accelerated computing and AI tools for drug discovery. These collaborations broaden QIAGEN’s platform capabilities and support adoption across clinical, research and biopharma workflows.

Image Source: Zacks Investment Research

What Ails QGEN Stock?Macro Risks and Demand Sensitivity: QIAGEN remains exposed to fluctuations in testing demand, research funding and customer capital spending across its global markets. In the second quarter of 2026, instrument sales declined at a low-teens CER rate as U.S. Life Sciences customers remained cautious. 

NIH funding in the first half of 2026 remained below year-ago levels despite sequential improvement in the second quarter. PCR/Nucleic Acid Amplification sales fell 8% at CER, reflecting weaker OEM demand and lower sales of other PCR products. These trends indicate that research funding and capital spending remain important variables for near-term growth, particularly in Life Sciences markets.

Competitive Intensity: QIAGEN operates in highly competitive molecular testing, sample preparation and bioinformatics markets, where established workflows may make share gains and platform conversions more difficult. This is particularly relevant as the company introduces new automation systems, syndromic testing panels and digital PCR offerings that depend on customer adoption and subsequent consumables pull-through. Competitive alternatives can lengthen sales cycles and limit the pace at which new platforms gain scale. Over time, QIAGEN’s growth will depend on converting product launches into sustained placements and recurring consumables demand across its core markets.

QGEN Stock Estimate TrendsThe Zacks Consensus Estimate for 2026 earnings per share (EPS) has remained unchanged at $2.43 in the past 30 days.

The Zacks Consensus Estimate for 2026 revenues is pegged at $2.14 billion, which indicates a modest 2.2% rise from the year-ago reported number.

Key PicksSome better-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Teleflex (TFX - Free Report) .

Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 28.2% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%. 

VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Globus Medical, flaunting a Zacks Rank #1 at present, has an earnings yield of 6.7% against the industry’s negative 1.4% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 27.3% against the industry’s 3.8% decline over the past year.

Teleflex, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 4% against the industry’s 3.7% decline over the past year.

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will hold an Extraordinary General Meeting of Shareholders on November 6, 2026, at 2:00 p.m. CET. Shareholders will be asked to vote on the appointment of Jonathan M. Pratt to the QIAGEN Managing Board after he joined QIAGEN as Chief Executive Officer on September 1, 2026. Subject to shareholder approval, Jon Pratt would join Roland Sackers, Chief Financial Officer, as the two me.

Qiagen N.V. (QGEN) 2026 Global Healthcare Conference September 15, 2026 9:00 AM EDT

Company Participants

Jonathan Pratt - CEO & Member of Management Board
Roland Sackers - CFO, MD & Member of Management Board
Domenica Martorana - Associate Director of Global Investor Relations

Conference Call Participants

Robert Bamberger - Robert W. Baird & Co. Incorporated, Research Division

Presentation

Robert Bamberger
Robert W. Baird & Co. Incorporated, Research Division

All right. Good afternoon, everyone. I'm Robby Bamberger, senior research analyst covering life sciences and diagnostics here at Baird. We're pleased to welcome QIAGEN this afternoon. Especially pleased to welcome Jon Pratt, who became QIAGEN's CEO on September 1. So we're catching him right at the 2-week mark. We also have Roland Sackers, QIAGEN's CFO and Domenica from IR with us as well. Thank you guys for all making the trip.

Question-and-Answer Session

Robert Bamberger
Robert W. Baird & Co. Incorporated, Research Division

Jon, just before we get into the business, I wanted to start with you. You stepped into the CEO seat September 1, so we're catching you 2 weeks in. What was it about QIAGEN that made you want this job? And in your conversation with the Supervisory Board, what were they telling you they wanted most for the next CEO of QIAGEN?

Jonathan Pratt
CEO & Member of Management Board

Yes. Thank you again. Good to be here. I guess I knew QIAGEN. I've been involved in the space through Pall and through Beckman Coulter and through Waters for a long time. I knew QIAGEN from an undergrad perspective. Almost every customer I touched was the blue boxes, so to speak. And so I knew the brand, did a bit of research on the brand and in terms of the customer intimacy and the quality of the people employed in QIAGEN, it was a pretty exciting place to come. So I

Qiagen N.V. (QGEN) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 1:05 PM EDT

Company Participants

Jonathan Pratt - CEO & Member of Management Board
Roland Sackers - CFO, MD & Member of Management Board
Domenica Martorana - Associate Director of Global Investor Relations

Conference Call Participants

Aisyah Noor - Morgan Stanley, Research Division

Presentation

Aisyah Noor
Morgan Stanley, Research Division

All right. Welcome, everyone, to our fireside chat with QIAGEN. I'm Aisyah Noor, Head of European MedTech Research at Morgan Stanley. It's my pleasure to host QIAGEN's CEO, Jonathan Pratt, and CFO, Roland Sackers today, as well as IR, Domenica Martorana. Before we start, I'm obligated to inform you to check ms.com/researchdisclosures for important disclosures and to check with your MS sales rep if you have any questions.

Question-and-Answer Session

Aisyah Noor
Morgan Stanley, Research Division

With that, welcome, John and Roland. It's great to have you here in New York. And Jonathan, for the first time as CEO of QIAGEN, very pleased to have you. If we kick off with your recent joining of QIAGEN, it's great that you've decided to join us here today. Could you briefly introduce yourself and why you decided to join this organization? And what do you see as the biggest opportunities in this business?

Jonathan Pratt
CEO & Member of Management Board

Okay. Well, thank you, Aisyah. Hello, everyone. Good to be here. Briefly introduce myself. As you can probably tell by the accent, I'm a Brit. I grew up in Europe, moved to the States in '01. In the industry, I was -- I spent a lot of my career at Pall Corporation, where I ran their laboratory businesses, some of the instrumentation businesses and their food and beverage businesses. From Pall, I ran as President of Beckman Coulter Life Sciences as part of Danaher and did that for a few years, moved to Florida in the process.

7.9.2026 18:07

Index DAX odepsal 0,15 % na 26 006,53 b.

Německý index DAX ve čtvrtek mírně oslabil. Největší růst zaznamenala německá polovodičová společnosti Infineon Technologies (+6,9 %) poté, co analytici z MP Capital Markets zvýšili doporučení ze stupně „hold“ na „buy“. Analytici však zároveň zachovali cílovou cenu pro akcie na 84 EUR. Dále se dařilo též společnostem HOCHTIEF (+2,5 %) a RWE (+2,0 %). Naopak odepisovaly společnosti Qiagen (-2,9 %), Munich Re (-2,8 %) a Hannover Re (-2,7 %).

Naopak nepatrně posílil celoevropský index STOXX Europe 600. Nejvíce přispěly k růstu sektory informačních technologií (+1,88 %), energií (+1,18 %) a průmyslu (+0,24 %). Naopak ztrácely sektory zdravotní péče (-1,05 %), nemovitostí (-0,89 %) a komunikačních služeb (-0,62 %).

Index DAX -0,15 % na 26006,53 b. Nejsilnější akcie Změna Nejslabší akcie Změna Infineon Technologies (IFX) +6,9 % Qiagen (QIA) -2,9 % HOCHTIEF AG (HOT) +2,5 % Munich Re (MUV2) -2,8 % RWE (RWE) +2,0 % Hannover Rueck SE (HNR1) -2,7 % Commerzbank AG (CBK) +1,6 % Vonovia (VNA) -2,2 % Siemens Energy (ENR) +1,3 % SAP (SAP) -1,6 % Zdroj: Bloomberg

Jan Prokeš
Fio banka, a.s.
Prohlášení

A SPECIAL WELCOME GIFT FROM ZACKS.COM Zacks' 7 Strongest Buys for September, 2026 See our "best of the best" short-term stocks. Hand-picked from 220 new Strong Buys, they could be the most profitable stocks you own over the next 90 days. Recent picks have climbed as much as +97.3% within 30 days. Our new recommendations may soar just as high.

A SPECIAL WELCOME GIFT FROM ZACKS.COM Zacks' 7 Strongest Buys for September, 2026 See our "best of the best" short-term stocks. Hand-picked from 220 new Strong Buys, they could be the most profitable stocks you own over the next 90 days. Recent picks have climbed as much as +97.3% within 30 days. Our new recommendations may soar just as high. Today's market dip makes now an ideal time to get in.

loading...

Primed to grow right now with long-term potential gains of 2X and more.

Primed to grow right now with long-term potential gains of 2X and more.

The pharmaceutical industry continues to grow thanks to an aging population and rising demand for new treatments. Which pharma stocks are best?

The pharmaceutical industry continues to grow thanks to an aging population and rising demand for new treatments. Which pharma stocks are best?

The airline industry covers a wide range of business models and opportunities. See our picks for the Best Airline Stocks to buy now.

The airline industry covers a wide range of business models and opportunities. See our picks for the Best Airline Stocks to buy now.

Here are our picks for the best publicly traded companies in the cryptocurrency business.

Here are our picks for the best publicly traded companies in the cryptocurrency business.

This oil and natural gas company has seen the Zacks Consensus Estimate for its current year earnings increase 241.2% over the last 60 days.

This oil and natural gas company has seen the Zacks Consensus Estimate for its current year earnings increase 241.2% over the last 60 days.

SPCX briefly reclaimed a $2 trillion market cap as Starlink growth, launch dominance and AI ambitions fueled investor optimism despite execution risks.

SPCX briefly reclaimed a $2 trillion market cap as Starlink growth, launch dominance and AI ambitions fueled investor optimism despite execution risks.

The consensus for today is expected to show August jobs up 55,000 (up 53K in the private sector and 2K in the public sector), while the unemployment rate is forecast at 4.2%.

The consensus for today is expected to show August jobs up 55,000 (up 53K in the private sector and 2K in the public sector), while the unemployment rate is forecast at 4.2%.

Amazon, AbbVie and Alibaba face contrasting growth drivers and challenges, from AI investment and drug launches to costly spending cycles.

Amazon, AbbVie and Alibaba face contrasting growth drivers and challenges, from AI investment and drug launches to costly spending cycles.

›

‹

Featured Zacks Rank Stocks Learn to Profit from the Zacks Rank

#1 Rank After transitioning from a crypto miner to an AI company, things are looking good.

#5 Rank Tobacco stocks have had a bit of a resurgence with the introduction of new products but analysts are starting to pump the b

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers Zacks #1 Rank Top Movers for Value Growth Momentum VGM Income Company Symbol Price %Chg Motorsport... MSGM 4.45 +10.70% EuroDry EDRY 55.14 +5.94% Abercrombie... ANF 149.62 +4.24% Polaris PII 63.46 +3.88% TAL Educati... TAL 12.36 +3.09% Zacks #1 Rank Top Movers7/16 The Zacks #1 Rank List is the best place to start your stock search each morning. It's made up of the top 5% of stocks with the most potential. Each weekday, you can quickly see the Zacks #1 Rank Top Movers from Value to Growth, Momentum and Income, even VGM Score.

Go to Zacks Rank #1 Top Movers

Full Zacks #1 Rank List8/16 You can see the full Zacks #1 Rank List or narrow it down to Zacks #1 Rank Stocks with a Value, Growth, Momentum or Income Style Score of A or B. Plus, you can see the Zacks #1 Rank Stocks with a VGM of A or B. You can also sort the list with criteria you choose, view Additions and Deletions by day, and Performance.

Go to the Zacks #1 Rank List

Zacks #1 Rank Additions Company (Symbol) Research Caterpillar (CAT) Analyst Report Dell Technologies (DELL) Analyst Report Robinhood Markets (HOOD) Analyst Report MongoDB (MDB) Analyst Report Aurora Cannabis (ACB) Snapshot Report Investment Ideas Earnings Analysis More Analysis Reported Earnings Surprises View All Positive Negative Symbol Time Expected Reported %Surprise KNOP 16:24 -0.03 0.10 +433.33 DLTH 05:49 -0.05 0.06 +220.00 PL 16:08 -0.02 0.02 +200.00 EGAN 16:19 0.03 0.08 +166.67 AOUT 16:15 -0.24 0.03 +112.50 EPS Positive Surprises for Sep 04, 2026

Symbol Time Expected Reported %Surprise CURV 16:06 -0.03 -0.04 -33.33 VBNK 07:04 0.34 0.27 -20.59 LE 06:46 0.10 0.09 -10.00 CPB 07:15 0.40 0.39 -2.50 EPS Negative Surprises for Sep 04, 2026

Upcoming Earnings ESP View More Symbol ESP Most Accurate Estimate Consensus Estimate AVO 21.74% 0.14 0.12 LMNR 5.26% 0.20 0.19 INNV 5.88% 0.09 0.09 Featured Stock Picks

Best Airline Stocks to Buy Now September 2026 The airline industry covers a wide range of business models and opportunities. See our picks for the Best Airline Stocks to buy now.

Best Crypto Stocks to Buy for September 2026 Here are our picks for the best publicly traded companies in the cryptocurrency business.

Best Pharmaceutical Stocks to Buy for September 2026 The pharmaceutical industry continues to grow thanks to an aging population and rising demand for new treatments. Which pharma stocks are best?

Best Biotech Stocks to Buy for September 2026 Biotech stocks are one of the most dynamic sectors in the market, combining scientific innovation with substantial financial opportunity. Here are some top current buys.

Best Gold Stocks to Buy for September 2026 Gold stocks, or shares of companies involved in mining or streaming the precious metal, offer investors a way to participate indirectly in gold price booms.

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction across diverse assay workflows. The platform delivers highly concentrated DNA and.

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. Jon Pratt most recently served as President and CEO of Filtration Group, leading the business through the completion of its sale to Parker-Hannifin Corpor.

19.8.2026 18:01

Index DAX klesl o 0,14 % na 26 091,33 b.

Německé akcie, měřené indexem DAX, ve středu oslabily o 0,14 % na 26 091,33 b.

Dařilo se akciím koncernu Volkswagen (+2,5 %), biotechnologické společnosti QIAGEN (+2,1 %) a softwarové společnosti SAP (+1,9 %). Naopak oslabovaly akcie polovodičové společnosti Infineon Technologies (-4,0 %), zbrojaře Rheinmetall (-2,9 %) a zajišťovny Hannover Re (-2,2 %).

Evropské akcie, měřené indexem STOXX Europe 600, jsou téměř beze změny, sektorově jde ale o rozpadlou emulzi, přičemž se daří základním materiálům (+1,92 %), zdravotní péči (+1,17 %) a zbytné spotřebě (+0,87 %). Naopak oslabují sektory IT (-1,27 %), financí (-1,18 %) a utilit (-1,02 %).

Index DAX -0,14 % na 26 091,33 b. Nejsilnější akcie Změna Nejslabší akcie Změna Volkswagen (VOW3) +2,5 % Infineon Technologies (IFX) -4,0 % Qiagen (QIA) +2,1 % Rheinmetall AG (RHM) -2,9 % SAP (SAP) +1,9 % Hannover Rueck SE (HNR1) -2,2 % Symrise (SY1) +1,6 % MTU Aero Engines (MTX) -2,1 % BASF (BAS) +1,6 % HOCHTIEF AG (HOT) -1,9 % Zdroj: Bloomberg

Michal Bárta
Fio banka, a.s.
Prohlášení

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance.

The clearance expands QIAGEN’s U.S. syndromic testing portfolio into bloodstream infection diagnostics, the fourth major infectious disease area covered by the QIAstat-Dx platform, which is available in more than 100 countries and with more than 5,200 cumulative placements as of the end of 2025.

The QIAstat-Dx BCID GPF Plus AMR Panel detects 20 gram-positive bacterial and fungal pathogen targets as well as a broad pan gram-negative target together with 10 genetic antimicrobial resistance markers from positive blood culture samples in about one hour. The rapid identification of pathogens and resistance gene markers can support informed treatment decisions, antimicrobial stewardship and infection prevention measures.

Bloodstream infections are associated with significant morbidity and mortality and can rapidly progress to sepsis, a life-threatening reaction to an infection that causes your immune system to harm healthy tissues and organs. An estimated 1.7 million adults in the U.S. develop sepsis each year1, highlighting the importance of providing clinicians with timely diagnostic information.

“Every hour, even minutes, count with bloodstream infections,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “This clearance gives U.S. laboratories a fast and integrated way to identify pathogens and key genetic antimicrobial resistance markers, supporting more informed treatment decisions and responsible antibiotic use. It also establishes the first member of a broader QIAstat-Dx bloodstream infection panel family planned for the U.S.”

The QIAstat-Dx system integrates sample preparation, multiplex PCR testing and data analysis into a single workflow. It is designed to provide rapid and easy-to-interpret results while reducing hands-on time for laboratory professionals.

The FDA clearance also lays the foundation for the continued expansion of QIAGEN’s bloodstream infection testing portfolio in the U.S. A complementary QIAstat-Dx BCID GN Plus AMR Panel, designed to detect gram-negative pathogens and associated genetic antimicrobial resistance markers, is currently under FDA review.

QIAGEN has been consistently expanding the QIAstat-Dx menu for the U.S., broadening the platform across four major infectious disease areas: respiratory, gastrointestinal, central nervous system and now bloodstream infections. The portfolio includes the QIAstat-Dx Respiratory Panel Plus, the QIAstat-Dx Respiratory Panel Mini, the QIAstat-Dx Gastrointestinal Panel 2, the QIAstat-Dx GI Panel 2 Mini B, the QIAstat-Dx GI Panel 2 Mini B&V, the QIAstat-Dx Meningitis/Encephalitis Panel and the newly FDA-cleared QIAstat-Dx BCID GPF Plus AMR Panel. This reflects QIAGEN's strategy of building a comprehensive infectious disease testing menu on a single integrated platform.

For more information about the QIAstat-Dx BCID GPF Plus AMR Panel and the QIAstat-Dx system, visit www.qiagen.com/applications/syndromic-testing.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of June 30, 2026, QIAGEN employed about 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. These include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to QIAGEN's filings with the U.S. Securities and Exchange Commission.

1 Centers for Disease Control and Prevention (CDC). About Sepsis. Available at: https://www.cdc.gov/sepsis/about/index.html (accessed August 2026).

Source: QIAGEN N.V.

Category: Infectious Diseases

More News From QIAGEN N.V.

10.8.2026 09:34, QIA

Index DAX +0,06 % na 26334,66 b.

Německé akcie měřené indexem DAX otevírají týden pozitivně.

GEA Group ve 2Q překonala očekávání trhu na hlavních ukazatelích. Očištěný zisk EBITDA dosáhl 251 mil. EUR oproti konsenzu 246,3 mil. EUR a EBITDA marže činila 17,4 % proti očekávaným 17,2 %. Tržby dosáhly 1,44 mld. EUR a objednávky 1,50 mld. EUR, v obou případech nad konsenzem trhu. Společnost zároveň ponechala celoroční výhled beze změny. Nadále očekává organický růst tržeb o 6 až 8 % a očištěnou EBITDA marži mezi 17,0 až 17,4 %. Akcie GEA Group +0,8 %.

Společnosti Qiagen byla analytikem Barclays zvýšena cílová cena z 38 USD na 40 USD. Doporučení bylo ponecháno na stupni „Equal-Weight“. Akcie Quaigen +2,5 %.

Index DAX +0,06 % na 26334,66 b. Nejsilnější akcie Změna Nejslabší akcie Změna Qiagen (QIA) +2,5 % Scout24 SE (G24) -1,3 % Infineon Technologies (IFX) +2,2 % Munich Re (MUV2) -1,1 % Siemens Energy (ENR) +1,7 % Beiersdorf AG (BEI) -1,0 % Allianz (ALV) +1,5 % Mercedes-Benz Group AG (MBG) -0,9 % Merck (MRK) +1,1 % Volkswagen (VOW3) -0,9 %
Zdroj: Bloomberg

Marek Krejčiřík
Fio banka, a.s.
Prohlášení

Související odkazy Německé akcie ve čtvrtek posílily Frankfurtská burza v úvodu mírně posiluje, společnost Deutsche Boerse reportovala za 1Q Frankfurtská burza v úvodu obchodování ztrácí Frankfurtská burza zakončila úterní seanci v záporu

Qiagen N.V. (QGEN) Q2 2026 Earnings Call Transcript

Qiagen (QGEN - Free Report) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.6 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +3.33%. A quarter ago, it was expected that this diagnostic products maker would post earnings of $0.55 per share when it actually produced earnings of $0.54, delivering a surprise of -1.82%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Qiagen, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $535.04 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.35%. This compares to year-ago revenues of $533.54 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Qiagen shares have lost about 10.6% since the beginning of the year versus the S&P 500's gain of 13%.

What's Next for Qiagen?While Qiagen has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Qiagen was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.64 on $552.19 million in revenues for the coming quarter and $2.43 on $2.14 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Opus Genetics, Inc. (IRD - Free Report) , has yet to report results for the quarter ended June 2026.

This company is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of -25%. The consensus EPS estimate for the quarter has been revised 1.5% lower over the last 30 days to the current level.

Opus Genetics, Inc.'s revenues are expected to be $3.02 million, up 5% from the year-ago quarter.

The market expects Qiagen (QGEN - Free Report) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The earnings report, which is expected to be released on August 5, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis diagnostic products maker is expected to post quarterly earnings of $0.60 per share in its upcoming report, which represents a year-over-year change of -4.8%.

Revenues are expected to be $527.94 million, down 1.1% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.78% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Qiagen?For Qiagen, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.28%.

On the other hand, the stock currently carries a Zacks Rank of #4.

So, this combination makes it difficult to conclusively predict that Qiagen will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Qiagen would post earnings of $0.55 per share when it actually produced earnings of $0.54, delivering a surprise of -1.82%.

Over the last four quarters, the company has beaten consensus EPS estimates two times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Qiagen doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsAmong the stocks in the Zacks Medical - Biomedical and Genetics industry, Rhythm Pharmaceuticals, Inc. (RYTM - Free Report) , is soon expected to post loss of $0.82 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of -9.3%. This quarter's revenue is expected to be $65.87 million, up 35.8% from the year-ago quarter.

The consensus EPS estimate for Rhythm Pharmaceuticals has remained unchanged over the last 30 days. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +1.46%.

When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Rhythm Pharmaceuticals will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

21.7.2026 09:35, DTG

Index DAX +0,12 % na 24876,12 b.

Německý index DAX otevírá úterní obchodování v mírně kladných hodnotách. Růst o 1,7 % si připisují akcie Daimler Truck Holding, když analytik z Kepler Cheuvreux změnil investiční doporučení z „reduce“ na „buy“.

Index DAX +0,12 % na 24876,12 b. Nejsilnější akcie Změna Nejslabší akcie Změna Infineon Technologies (IFX) +2,2 % Qiagen (QIA) -2,0 % Daimler Truck Holding AG (DTG) +1,7 % Siemens Healthineers (SHL) -1,7 % Rheinmetall AG (RHM) +1,2 % Scout24 SE (G24) -1,3 % Deutsche Post AG (DHL) +1,0 % Merck (MRK) -1,1 % Fresenius Medical Care (FME) +0,9 % Brenntag (BNR) -0,9 % Zdroj: Bloomberg

Jakub Němec
Fio banka, a.s.
Prohlášení

Související odkazy DAX uzavírá čtvrtek v záporu, Rheimetall reportoval kvartální čísla Shrnutí kvartálních výsledků z indexu DAX Frankfurtská burza v úvodu čtvrtečního obchodování mírně posiluje Frankfurtská burza druhou seanci v řadě posílila, Daimler Truck vybuduje v Chebu nový závod Frankfurtská burza otevírá seanci v záporném teritoriu

GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis cases reported across the United States.

More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May, along with another 7,000 potential cases, as health authorities investigate multiple outbreaks involving Cyclospora cayetanensis, a foodborne parasite that can cause prolonged diarrhea and other gastrointestinal symptoms. The parasite is not detected through routine stool culture and requires specialized diagnostic methods, including molecular testing.

QIAGEN's Sample to Insight portfolio supports laboratories across the molecular testing continuum, from syndromic diagnostics and digital PCR to next-generation sequencing (NGS):

The FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 includes Cyclospora cayetanensis as a standard target within its 16-target menu for bacterial, viral and parasitic pathogens. The fully integrated syndromic test delivers results in about an hour, enabling laboratories to test for Cyclospora alongside other common causes of gastrointestinal illness from the initial patient sample. For research use only, QIAGEN offers the digital PCR Microbial DNA Detection Assay targeting Cyclospora cayetanensis for use with the QIAcuity digital PCR system, supporting highly sensitive detection in research and public health applications. QIAGEN's sequencing portfolio also includes the PulseNet-approved QIAseq FX DNA Library Prep Kit for research use only with any NGS sequencer. This kit is designed to support “shotgun sequencing workflows” that analyze all DNA in a sample to help identify and characterize foodborne pathogens for PulseNet, the U.S. public health laboratory network that detects and investigates foodborne disease outbreaks. “The current rise in cyclosporiasis cases highlights the need for rapid, reliable detection to support timely patient care and effective public health action,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “QIAGEN is ready to support laboratories and public health authorities worldwide with molecular testing technologies that help detect infections, guide investigations and strengthen responses to emerging disease threats.”

Further information about QIAGEN's molecular testing solutions supporting clinical diagnostics, research and public health laboratories is available through local QIAGEN representatives or the QIAGEN Customer Care team on www.qiagen.com.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of June 30, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Source: QIAGEN N.V.

Category: Infectious Diseases

More News From QIAGEN N.V.

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel, establishing a comprehensive bloodstream infection testing offering on the QIAstat-Dx platform in Europe.

The new QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance (AMR) markers from positive blood cultures in about one hour. It complements the recently launched QIAstat-Dx BCID GPF Plus AMR Panel in Europe, extending QIAGEN's bloodstream infection testing coverage across gram-positive bacteria, gram-negative bacteria, fungi and key AMR markers. Together, the two panels detect 33 pathogen targets and 28 AMR markers, enabling rapid identification of the most clinically relevant bloodstream pathogens and resistance mechanisms to support earlier pathogen identification and clinical decision-making.

“Every hour matters when treating bloodstream infections, particularly when AMR is involved,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “Together, our complementary BCID panels provide comprehensive molecular coverage of the pathogens and resistance mechanisms most relevant to bloodstream infections. By delivering results in about one hour, they help laboratories support faster treatment decisions, antimicrobial stewardship and effective infection control.”

Gram-negative pathogens are among the leading causes of bloodstream infections and are frequently associated with AMR, one of the world's most significant public health threats. AMR occurs when bacteria develop mechanisms that render antibiotics ineffective, making infections more difficult to treat and increasing the risk of severe illness and death. In bloodstream infections, delays in identifying resistant pathogens can postpone appropriate therapy, while the growing burden of beta-lactam resistance driven by extended-spectrum beta-lactamase (ESBL) and carbapenemase-producing organisms underscores the need for rapid and accurate detection. With broad coverage of key beta-lactam resistance mechanisms, the QIAstat-Dx BCID GN Plus AMR Panel provides rapid, actionable molecular insights to support optimized treatment decisions and infection control.

The QIAstat-Dx BCID GN Plus AMR Panel is CE-IVDR certified and available in applicable markets. Regulatory review by the U.S. Food and Drug Administration is underway.

QIAGEN's CE-IVDR-certified QIAstat-Dx menu in Europe spans key syndromic testing areas, including respiratory infections, gastrointestinal infections, central nervous system infections through its meningitis / encephalitis panel and bloodstream infection testing. With the addition of the BCID GN Plus AMR Panel, the QIAstat-Dx platform now provides comprehensive bloodstream infection testing through complementary gram-positive and gram-negative panels. Built around rapid, cartridge-based molecular testing, QIAstat-Dx integrates sample preparation, molecular analysis and result interpretation into a streamlined workflow, helping laboratories generate clinically relevant insights across a growing range of infectious disease applications.

QIAstat-Dx systems are available in more than 100 countries, with more than 5,200 instruments placed worldwide as of the end of 2025.

For more information about the QIAstat-Dx BCID GN Plus AMR Panel and the QIAstat-Dx system, visit https://www.qiagen.com/de-us/applications/syndromic-testing.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Source: QIAGEN N.V.

Category: Infectious Diseases

More News From QIAGEN N.V.

9.7.2026 17:58, RHM, QIA

Index DAX přidal 0,87 % na 25114,37 b.

Německé akcie, měřené indexem DAX, ve čtvrtek posílily o 0,87 %. Nejvíce rostly akcie Qiagen (+10,6 %), Infineon Technologies (+4,3 %) a Zalando (+3,4 %). Společnost Qiagen, zabývající se molekulárním testováním, podle informací osob obeznámených s problematikou přitahuje předběžný zájem o převzetí ze strany firem včetně EQT a Advent.

Naopak nejvíce oslabily akcie firem Rheinmetall (-4,3 %), Deutsche Boerse (-1,4 %) a Daimler Truck Holding (-1,3 %). Akcie evropských obranných společností klesaly poté, co summit NATO v Turecku přinesl nižší výdajové závazky, než investoři doufali, přičemž analytik Alessandro Pozzi z Mediobanca označil omezené zvýšení výdajů ve Španělsku a Itálii za poněkud zklamávající. Jens-Peter Rieck z mwb Research navíc snížil doporučení pro akcie Rheinmetall na stupeň „hold“ z původního „buy“ s tím, že pozemní systémy ztratily prioritu. Bulharská vláda navíc podle zpráv zpravodajského webu Mediapool s odvoláním na ministra hospodářství Alexandera Puleva možná nebude schopna zajistit financování společného projektu s firmou Rheinmetall na závod na výrobu prachové náplně a dělostřeleckých granátů standardu NATO.

Celoevropský index STOXX Europe 600 si připisuje 0,76 %. Z jednotlivých sektorů vykazují největší růst informační technologie (+4,15 %), materiály (+1,35 %) a finance (+1,30 %). Naopak v záporném teritoriu se pohybují sektory energií (-1,11 %), zdravotní péče (-1,09 %) a nezbytného spotřebního zboží (-0,98 %).

Index DAX +0,87 % na 25114,37 b. Nejsilnější akcie Změna Nejslabší akcie Změna Qiagen (QIA) +10,6 % Rheinmetall AG (RHM) -4,3 % Infineon Technologies (IFX) +4,3 % Deutsche Boerse (DB1) -1,4 % Zalando (ZAL) +3,4 % Daimler Truck Holding AG (DTG) -1,3 % Siemens (SIE) +3,1 % Volkswagen (VOW3) -1,2 % Siemens Energy (ENR) +2,9 % Munich Re (MUV2) -1,2 % Zdroj: Bloomberg

Michal Šnobl
Fio banka, a.s.
Prohlášení